ARID1A (BAF250a) (EP303) Rabbit Monoclonal Antibody

ARID1A (BAF250a)
Endometrial carcinoma stained with anti-ARID1A

ARID1A (BAF250a) (EP303) Rabbit Monoclonal Antibody

Updated: 2017-05-24 08:46:09

ARID1A (AT-rich interactive domain-containing protein 1A), also known as BAF250a, is a recently identified tumor suppressor that is a component of the SWI/SNF chromatin remodeling complex. ARID1A functions by binding AT-rich DNA sequences to regulate gene expression of nucleosome mobilization and chromatin processes. While ARID1A is typically expressed in most normal tissues, it is frequently mutated in a multitude of tumors, including breast, lung, gastric, renal and ovarian cancers.

Genomic sequencing revealed that most ARID1A mutations are truncating mutations, and the presence of mutations is highly correlative with loss of ARID1A protein expression by immunohistochemistry. Deficient ARID1A expression was observed in approximately 70% of renal cell carcinomas, 50% of gastric cancers, 40% of clear cell ovarian carcinomas, and 40% of endometrioid carcinomas. Furthermore, loss of ARID1A expression was determined as an independent marker for poor prognosis; tumors were correlated with higher stage and grade, are more likely to be chemoresistant, and associated with shorter progression-free and overall survival rates. ARID1A antibody may be used for identifying ARID1A defect tumors.


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: Colon
  • Dilution Range: 1:100 - 1:200*

Package Inserts

IFU included with product

Download your SDS


Ordering Information

For in vitro diagnostic (IVD) use in USA

1 mL concentrateAC-0275
0.1 mL concentrateAC-0275A

This product is not available in Canada

For in vitro diagnostic (IVD) use in Europe

1 mL concentrateAC-0275
0.1 mL concentrateAC-0275A

For research use only (RUO) in Japan

1 mL concentrateAC-0275
0.1 mL concentrateAC-0275A


To request information on this product in additional countries, please click the button below.

Request More Information